SocietyCEO turned informant: How the FDA built a case against executives promising cheap medications
A court record says the FDA’s unprecedented criminal case against an alternative funding program hinged on cooperation from a fellow CEO.
CEO turned informant: How the FDA built a case against executives promising cheap medications
Society